Abstract
Susceptibility to the development of Alzheimer’s disease (AD) is increased for individuals harboring one or more apolipoprotein E4 (apoE4) alleles. Even though several isoform-specific effects of apoE have been identified, the relationship between biochemical function and risk factor assessment remains unknown. Our previous studies have demonstrated that there is an equilibrium between cerebral spinal fluid (CSF) and plasma β-amyloid (Aβ) and that amyloid plaques can modify this equilibrium. Trafficking of soluble central nervous system (CNS) Aβ is a very dynamic system that almost certainly is modulated by Aβ-binding proteins. Altered trafficking of the Aβ peptide might have a dramatic consequence as to whether the peptide is metabolized or begins to deposit within the brain. To gain a better understanding of the molecular mechanisms by which apoE influences AD pathogenesis and/or Aβ trafficking, we developed PDAPP transgenic mice that express different levels of human apoE3. Analysis of the soluble CNS pools of Aβ in young mice showed an apoE3 dose-dependent decrease in Aβ levels (E3−/−>E3−/−>E3+/+). In addition to the dose-dependent effects on soluble Aβ, by 15 mo of age there were highly significant differences in the amount of deposited Aβ between the genotypes (E3−/−>E3−/−>E3+/+). These data indicate that apoE3 provides a dose-dependent protective effect against Aβ deposition. This study suggests that increasing human apoE levels in brain might be a possible therapeutic target for preventing AD.
Similar content being viewed by others
References
Bales K. R., Du Y., Holtzman D. M., Cordell B., and Paul S. M. (2000) Neuroinflammation and Alzheimer’s disease: critical roles for cytokine/Aβ-induced glial activation, NF-κB, and apolipoprotein E. Neurobiol. Aging 21, 427–432.
Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263–264.
Buttini M., Orth M., Bellosta S., Akeefe H., Pitas R. E., Wyss-Coray T., et al. (1999) Expression of human apolipoprotein E3 or E4 in the brains of apoE/mice: isoform-specific effects on neurodegeneration. J. Neurosci. 19, 4867–4880.
Chen Y., Lomnitski L., Michaelson D. M., and Shohami E. (1997) Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience 80, 1255–1262.
Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923.
Dawson P. A., Schechter N., and Williams D. L. (1986) Induction of ratE and chicken A-1 apolipoproteins and mRNAs during optic nerve degeneration. J. Biol. Chem. 261, 5681–5684.
DeMattos R. B., Bales K. R., Cummins D. J., Dodart J.-C., Paul S. M., and Holtzman D. M. (2001a) Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855.
DeMattos R. B., Bales K. R., Parsadanian M., Kierson M. E., O’Dell M. A., Foss E. M., et al. (2002a) Plaque-associated disruption of CSF and plasma Aβ equilibrium in a mouse model of Alzheimer’s Disease. J. Neurochem. 81, 229–236.
DeMattos R. B., Brendza R. P., Heuser J. E., Kierson M., Cirrito J. R., Fryer J. D., et al. (2001b) Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem. Int. 39, 415–425.
DeMattos R. B., Curtiss L. K., and Williams D. L. (1998) A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J. Biol. Chem. 273, 4206–4212.
DeMattos R. B., Parsadanian M., O’Dell M. A., Taylor J. W., Bales K. R., Paul S. M., and Holtzman D. M. (2002b) Apolipoprotein E3 dose dependent modulation of Amyloid-beta deposition in a transgenic mouse model of Alzheimer’s disease. Soc. Neurosci. Abstr. 32, 723.
DeMattos R. B., Rudel L. L., and Williams D. L. (2001c) Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth. J. Lipid Res. 42, 976–987.
DeMattos R. B., Thorngate F. E., and Williams D. L. (1999) A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. J. Neurosci. 19, 2464–2473.
Evans K. C., Berger E. P., Cho C.-G., Weisgraber K. H., and Lansbury P. T. (1994) Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 92, 763–767.
Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M., and Holtzman D. M. (2002) Human and murine apoE markedly influence Aβ metabolism both prior and subsequent to plaque formation in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 9, 305–318.
Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523–527.
Ghersi-Egea J.-F., Gorevic P. D., Ghiso J., Frangione B., Patlak C. S., and Fensternacher J. D. (1996) Fate of cerebrospinal fluid-borne amyloid β-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries. J. Neurochem. 67, 880–883.
Greenberg S. M., Briggs M. E., Hyman B. T., Kokoris G. J., Takis C., Kanter D. S., et al. (1996) Apolipoprotein E ε4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 27, 1333–1337.
Greenberg S. M., Rebeck G. W., Vonsattel J. P. G., Gomez-Isla T., and Hyman B. T. (1995) Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38, 254–259.
Holtzman D. M. and Fagan A. M. (1998) Potential role of apoE in structural plasticity in the nervous system: implications for diseases of the central nervous system. Trends Cardiovasc. Med. 8, 250–255.
Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., et al. (2000a) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 97, 2892–2897.
Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., et al. (1999) In vivo expression of apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimers disease. J. Clin. Invest. 103, R15-R21.
Holtzman D. M., Fagan A. M., Mackey B., Tenkova T., Sartorius L., Paul S. M., et al. (2000b) ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer’s disease. Ann. Neurol. 47, 739–747.
Ignatius M. J., Gebicke-Harter P. J., Skene J. H. P., Schilling J. W., Weisgraber K. H., Mahley R. W., and Shooter E. M. (1986) Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. USA 83, 1125–1129.
Ji Y., Permanne B., Sigurdsson E. M., Holtzman D. M., and Wisniewski T. (2001) Amyloid β40/42 clearance across the blood-brain barrier following intraventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimers Dis. 3, 23–30.
Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., et al. (1997) Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 94, 1550–1555.
Jordán J., Galindo M. F., Miller R. J., Reardon C. A., Getz G. S., and LaDu M. J. (1998) Isoform-specific effect of apolipoprotein E on cell survival- and amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18, 195–204.
LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., and Frail D. E. (1994) Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269, 23404–23406.
LaDu M. J., Pederson T. M., Frail D. E., Reardon C. A., Getz G. S., and Falduto M. T. (1995) Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270, 9030–9042.
Laskowitz D. T., Sheng H., Bart R. D., Joyner K. A., Roses A. D., and Warner D. S. (1997) Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17, 753–758.
Mahley R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–630.
Masliah E., Samuel W., Veinbergs I., Mallory M., Mante M., and Saitoh T. (1997) Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 751, 307–314.
Miyata M. and Smith J. D. (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat. Genet. 14, 55–61.
Nathan B. P., Bellosta S., Sanan D. A., Weisgraber K. H., Mahley R. W., and Pitas R. E. (1994) Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850–852.
Newman T. C., Dawson P. A., Rudel L. L., and Williams D. L. (1985) Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J. Biol. Chem. 260, 2452–2457.
Nicoll J. A. R., Roberts G. W., and Graham D. I. (1995) ApoE E4 allele is associated with deposition of amyloid beta-protein following head injury. Nat. Med. 1, 135–137.
Pitas R. E., Boyles J. K., Lee S. H., Hui D., and Weisgraber K. H. (1987) Lipoproteins and their receptors in the central nervous system. J. Biol. Chem. 262, 14352–14360.
Poirier J. (1994) Apolipoprotein E in animal models of CNS injury and Alzheimer’s disease. Trends Neurosci. 17, 525–530.
Poirier J., Baccichet A., Dea D., and Gauthier S. (1993) Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats. Neuroscience 55, 81–90.
Puttfarcken P. S., Manelli A. M., Falduto M. T., Getz G. S., and LaDu M. J. (1996) Effect of apolipoprotein E on neurite outgrowth and β-amyloid induced toxicity in developing rat primary hippocampal cultures. J. Neurochem. 68, 760–769.
Rea T. J., DeMattos R. B., and Pape M. E. (1993) Hepatic expression of genes regulating lipid metabolism in rabbits. J. Lipid Res. 34, 1901–1910.
Rebeck G. W., Kindy M., and LaDu M. J. (2002) Apolipoprotein E and Alzheimer’s disease: the protective effects of ApoE2 and E3. J. Alzheimers Dis. 4, 145–154.
Rebeck G. W., Reiter J. S., Strickland D. K., and Hyman B. T. (1993) Apolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron 11, 575–580.
Schmechel D. E., Saunders A M., Strittmattter W. J., Crain B. J., Hulette C. M., Joo S. H., et al. (1993) Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649–9653.
Selkoe D. J. (1994a) Alzheimer’s disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53, 438–447.
Selkoe D. J. (1994b) Normal and abnormal biology of the beta-amyloid precursor protein. Ann. Rev. Neurosci. 17, 489–517.
Selkoe D. J. (1997) Alzheimer’s disease: genotypes, phenotype, and treatments. Science 275, 630–631.
Selkoe D. J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766.
Shibata M., Yamada S., Kumar S. R., Calero M., Bading J., Frangione B., et al. (2000) Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489–1499.
Sisodia S. S. (1999) Alzheimer’s disease: perspectives for the new millennium. J. Clin. Invest. 104, 1169–1170.
Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., and Finch C. E. (1998) Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer’s disease. J. Neurosci. 18, 3180–3185.
Stone D. J., Rozovsky I., Morgan T. E., Anderson C. P., Hajian H., and Finch C. E. (1997) Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143, 313–318.
Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., and Roses A. D. (1993a) Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977–1981.
Strittmatter W. J., Weisgraber K. H., Huang D. Y., Dong L.-Y., Salvesen G. S., Pericak-Vance M., et al. (1993b) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform specific-effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 8098–8102.
Sun Y., Wu S., Bu G., Onifade M. K., Patel S. N., LaDu M. J., et al. (1998) GFAP-apoE transgenic mice: astrocyte specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 18, 3261–3272.
Teter B., Harris-White M. E., Frautschy S. A., and Cole G. M. (1999) Role of apolipoprotein E and estrogen in mossy fiber sprouting in hippocampal slice cultures. Neuroscience 91, 1009–1016.
Teter B., Raber J., Nathan B., and Crutcher K. A. (2002) The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J. Alzheimers Dis. 4, 155–163.
Tolar M., Keller J. N., Chan S., Mattson M. P., Marques M. A., and Crutcher K. A. (2000) Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 19, 7100–7110.
Weisgraber K. H. (1994) Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45, 249–302.
Williams D. L., Dawson P. A., Newman T. C., and Rudel L. L. (1985) Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J. Biol. Chem. 260, 2444–2451.
Wisniewski T., Castano E. M., Golabek A., Vogel T., and Frangione B. (1994) Acceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145, 1030–1035.
Zlokovic B. V., Ghiso J., Mackic J. B., McComb J. G., Weiss M. H., and Frangione B. (1993) Blood-brain barrier transport of circulating Alzheimer’s amyloid β. Biochem. Biophys. Res. Commun. 197, 1034–1040.
Zlokovic B. V., Martel C. L., Mackic J. B., Matsubara E., Wisniewski T., McComb J. G., et al. (1994) Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer’s amyloid β. Biochem. Biophys. Res. Commun. 205, 1431–1437.
Zlokovic B. V., Martel C. L., Matsubara E., McComb J G., Zheng G., McCluskey R. T., et al. (1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer’s disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA 93, 4229–4234.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
DeMattos, R.B. Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer’s disease. J Mol Neurosci 23, 255–262 (2004). https://doi.org/10.1385/JMN:23:3:255
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/JMN:23:3:255